Yakatenderwa Kurapa Kwekudzokerazve uye Refractory Multiple Myeloma

MuAustralia vanhu vanosvika zviuru zviviri nemazana mana vanoonekwa gore rega rega vane multiple myeloma (MM), uye varwere vanosvika zviuru makumi maviri vari kurarama neMM chero nguva. Nehurombo, varwere vanopfuura 2,400 vachafa nerudzi urwu rwegomarara reropa mune chero gore rakapihwa uye saka nzira itsva dzekurapa dzakaita seXPOVIO® dzinodiwa.              

Antengene Corporation Limited nhasi yakazivisa kuti Therapeutic Goods Administration (TGA) yeAustralia Government Department of Health yakanyoresa XPOVIO® (selinexor) yezviratidzo zviviri: (1) Mukubatana nebortezomib uye dexamethasone (XBd) yekurapa varwere vakuru vane multiple myeloma (MM) vakagamuchira kanenge kamwe chete kurapa kwekutanga uye (2) pamwe chete nedexamethasone (Xd) yekurapa varwere vakuru vane kudzokazve uye / kana refractory multiple myeloma (R/R MM) vakagamuchira kanenge katatu. vasati vatanga kurapwa uye vane chirwere chinoramba kune imwechete proteasome inhibitor (PI), ingangoita imwe immunomodulatory medicinal product (IMiD), uye anti-CD38 monoclonal antibody (mAb).

XPOVIO® ndiyo yekutanga uye yega SINE yakatenderwa neTGA inobatsira kudzoreredza muviri wega bundu suppressor nzira.

Purofesa Hang Quach, chiremba weHematologist paSt Vincent's Hospital, Melbourne, akati, “Ndakava neropafadzo yekuva mumwe wevaongorori muongororo yekiriniki yeBOSTON uye kubvira ipapo ndakanyora pamwe chete pamapepa mashoma echirongwa cheXBd. Iyi chirongwa chetatu hapana mubvunzo mupfungwa dzangu pakati peakanyanya kurapa ekutanga kudzoka munguva ye lenalidomide refractoriness. Pakuongororwa kweseti, chirongwa chetatu ichi chinoshanda zvisinei nezera, varwere vasina kusimba kana vasina kusimba uye inoshanda kune varwere vane yakaderera creatinine clearance. Zvinonyanya kukosha, kusanganiswa kweXBd kwainyanya kushanda kune varwere vane ngozi yakawanda ye cytogenetics.

Purofesa Hang Quach akatizve "Ndinotenda kuti mitsara mitatu yekutanga yekurapa kweMM ndiyo inonyanya kukosha pakutaura hupenyu hwese hwemurwere nokuti ruzhinji rwevarwere vane MM mumamiriro ezvinhu chaiwo havazorarami kuti vaone mutsara wechina wekurapa mhiri. Zvakare, iyo yakanyanya kubhenefiti yekiriniki inowanikwa kana kurapwa kunoshanda kunoshandiswa mukutanga-mutsara kudzoka. Saka zvakakosha kuti murapi apihwe sarudzo yakakwana munzvimbo “yemutsara mumwe kusvika kunhatu” kuti abvumire chirongwa chepamusoro-soro kuti chishandiswe zvichienderana nemamiriro ehutano hwemurwere. Kushaikwa kwesarudzo dzakakwana kune varwere vane lenalidomide-refractory mukutanga-mutsara kudzoka kweMM inzvimbo yekusada kudiwa muAustralia. Kuvepo kweXPOVIO®, bortezomib uye dexamethasone sechisarudzo munzvimbo ino kuchagadzirisa chinodiwa ichi.

"MuAustralia, imwe nzvimbo yakakosha yekuda kusingakwane kwevarwere vane myeloma kushaikwa kwekurapa kunoshanda kune varwere vane katatu-class refractory, iyo inopikisa kune proteasome inhibitor, immunomodulatory drug uye anti-CD38 monoclonal antibody. Kubatsira kweXPOVIO® nderekuti mushonga wemukanwa une hunyanzvi hwekuita hwekuita hunoita kuti ive yakanakira varwere vekirasi-vatatu vanoramba. XPOVIO® inogona kuunza mhinduro uye kurebesa hupenyu nenzira ine chinangwa chekiriniki ”, akadaro Muzvinafundo Andrew Spencer, Haematologist, Alfred Hospital, Melbourne.

Hayley Beer, Interim Co-CEO weMyeloma Australia, akati “Zvakakosha kwazvo kuve neimwe nzira yekurapa kune vanhu vanorarama nemultiple myeloma, mumitsetse yekutanga uye yakazotevera yekurapa. XPOVIO® ikirasi nyowani yemishonga ine yakasarudzika nzira yekuita, saka zvinoreva kuti varwere vanogona kuedza musanganiswa mutsva pasina kudzoreredza kirasi yakamboshandiswa yemishonga.

"Ichi chiitiko chakakosha kuAntengene uye kuvarwere veMM muAustralia. Isu tinofara kwazvo kuve nekutanga XPOVIO® uye kuunza kuvarapi vekuAustralia nevarwere imwe yekuwedzera kune yavo iripo regimens yekurapwa kweR/R MM. Sechigadzirwa chedu chekutanga kunyoreswa muAustralia, inoratidzawo kushanduka kweAntengene muAustralia kuita sangano rebiopharmaceutical rine kuzvipira kuenderera mberi nekusimudzira uye kutengeserana kwemishonga inoshandura kenza nezvimwe zvirwere zvinouraya muAustralia, "akadaro Thomas Karalis. CVP Asia Pacific yeAntengene.

"Nhevedzano yemvumo yakapihwa kuXPOVIO® kuChina, South Korea, Singapore uye ikozvino Australia mumwedzi mitanhatu yapfuura yakaratidza kugona kukuru kwemushonga uyu pakurapa. MuAustralia, kune vanosvika zviuru zviviri nemazana mana vanobatwa neMM gore rega rega, nekudaro vachipa rubatsiro rwechimbichimbi mukurapwa kweMM, "akadaro Jay Mei, Muvambi weAntengene, Sachigaro uye CEO. "Kubvumidzwa uku neTGA kuri kushandura-kuchinja kune varwere muAustralia vagara vachirwara neMM. Takazvipira kuunza mishonga yemhando yepamusoro uye marapiro kuvarwere vane gomarara kana zvimwe zvirwere zvinouraya mudunhu reAsia Pacific nepasirese. Ikozvino, timu yedu yezvokutengeserana yakanyatso gadzirira kuwedzera mukana wevarwere kuwana iyi novel therapy, tichivaka pamusoro peruzivo rwedu rwekutengesa neXPOVIO® kutanga kuChina, Singapore neSouth Korea.